Drug name - Yupelri
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7585879 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US7910608 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US7288657 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Dec, 2025
(3 years from now) | |
| US10550081 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(7 years from now) | |
| US9765028 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(7 years from now) | |
| US8541451 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Aug, 2031
(8 years from now) | |
| CN1930125B | MYLAN IRELAND LTD | Biphenyl Compounds Useful As Muscarinic Receptor Antagonists |
Mar, 2025
(2 years from now) | |
| CN1930125A | MYLAN IRELAND LTD | Biphenyl Compounds Useful As Muscarinic Receptor Antagonists |
Mar, 2025
(2 years from now) | |
| CN102470130A | MYLAN IRELAND LTD | Crystalline Freebase Forms Of A Biphenyl Compound |
Jul, 2030
(7 years from now) | |
| CN102470130B | MYLAN IRELAND LTD | Biphenyl Compound Is Crystalline Free Base Form |
Jul, 2030
(7 years from now) | |
| IN249707B | MYLAN IRELAND LTD | A Biphenyl Compound Of Formula (I) |
Mar, 2025
(2 years from now) | |
| IN200604657P1 | MYLAN IRELAND LTD | Biphenyl Compounds Useful As Muscarinic Receptor Antagonists |
Mar, 2025
(2 years from now) | |
| EP1723114A1 | MYLAN IRELAND LTD | Biphenyl Compounds Useful As Muscarinic Receptor Antagonists |
Mar, 2025
(2 years from now) | |
| EP1930323A1 | MYLAN IRELAND LTD | Biphenyl Compounds Useful In The Synthesis Of Muscarinic Receptor Antagonists |
Mar, 2025
(2 years from now) | |
| EP1723114B1 | MYLAN IRELAND LTD | Biphenyl Compounds Useful As Muscarinic Receptor Antagonists |
Mar, 2025
(2 years from now) | |
| EP1930323B1 | MYLAN IRELAND LTD | Biphenyl Compounds Useful In The Synthesis Of Muscarinic Receptor Antagonists |
Mar, 2025
(2 years from now) | |
| EP2987490B1 | MYLAN IRELAND LTD | Crystalline Freebase Forms Of A Biphenyl Compound |
Jul, 2030
(7 years from now) | |
| EP2453894B1 | MYLAN IRELAND LTD | Crystalline Freebase Form Of A Biphenyl Compound |
Jul, 2030
(7 years from now) | |
| EP2987490A1 | MYLAN IRELAND LTD | Crystalline Freebase Forms Of A Biphenyl Compound |
Jul, 2030
(7 years from now) | |
| EP2453894A1 | MYLAN IRELAND LTD | Crystalline Freebase Form Of A Biphenyl Compound |
Jul, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7491736 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US7521041 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US10106503 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US10343995 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US8053448 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US8273894 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US11247969 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US8034946 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US7550595 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US11008289 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(7 years from now) | |
Drugs and Companies using REVEFENACIN ingredient
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION;INHALATION
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 175MCG/3ML | SOLUTION;INHALATION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.